Loading
  • Pipeline Pipeline
    • Pipeline Chart
    • Camsirubicin
      • Overview
      • Clinical Data
      • Development Strategy
      • MNPR-201-001 Clinical Trial
    • MNPR-101 RIT & MNPR-101-Zr
    • MNPR-101
      • Overview
      • Development Strategy
    • MNPR-202
    • Collaborations
      • Overview
      • Current Collaborations
    • Intellectual Property
    • Publications
      • Camsirubicin
      • MNPR-101
  • Investors Investors
    • Overview
    • Annual Meeting
    • News / Events
      • Press Releases
      • IR Calendar
      • In the News
      • Email Alerts
    • Company Information
      • Profile
      • Presentations
      • Our Team
      • FAQ
    • Stock Data
      • Quote
      • Charts
      • Historical Data
      • Analyst Coverage
    • SEC Filings
      • All SEC Filings
      • Annual Reports
      • Quarterly Reports
      • Section 16 Filings
    • Corporate Governance
      • Board of Directors
      • Board Committees
      • Governance Documents
  • Our Team Our Team
  • Contact Us Contact Us
  • Home
  • Investors
  • News / Events
  • Press Releases
Investors

Investors

  • Overview
  • Annual Meeting
  • News / Events
    • Press Releases
    • IR Calendar
    • In the News
    • Email Alerts
  • Company Info
    • Profile
    • Presentations
    • Our Team
    • FAQ
  • Stock Data
    • Quote
    • Charts
    • Historical Data
    • Analyst Coverage
  • SEC Filings
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
  • Governance
    • Board of Directors
    • Board Committees
    • Governance Documents
  • Investor Tools
    • Email Alerts
    • Tear Sheet
    • Contacts
    • RSS News Feed
  • News / Events

  • Press Releases
  • IR Calendar
  • In the News
  • Email Alerts

Press Releases

Monopar Announces Promising MNPR-202 Data from Ongoing National University of Singapore Collaboration

Dec 12, 2022

Monopar Announces Encouraging Clinical Data from Ongoing Camsirubicin Phase 1b Trial

Nov 16, 2022

Monopar Therapeutics Reports Third Quarter 2022 Financial Results and Recent Program Developments

Nov 10, 2022

Monopar Announces Timeline of Upcoming Data Events for Validive, Camsirubicin, and MNPR-202

Oct 27, 2022

Monopar Announces Presentation Selected for 2022 American Society of Hematology (ASH) 64th Annual Meeting

Oct 19, 2022

Monopar Announces Presentation Selected for 2022 Connective Tissue Oncology Society (CTOS) Annual Meeting

Oct 12, 2022

Monopar Announces Completion of Phase 2b Enrollment and Commencement of Phase 3 Enrollment in its VOICE Trial for Severe Oral Mucositis

Oct 5, 2022

Monopar to Present at Roth Inaugural Healthcare Opportunities Conference

Sep 28, 2022

Monopar Therapeutics Reports Second Quarter 2022 Financial Results and Recent Program Developments

Aug 11, 2022

Monopar Therapeutics Reports First Quarter 2022 Financial Results and Recent Program Developments

May 12, 2022
RSS
    • 1
    • 2
    • 3
    • 4
    • 5
    • 6
    • 7
    • 8
    • About
    • Pipeline
    • Investors
    • Our Team
    • Contact Us
    • Pipeline
    • Pipeline Chart
    • Camsirubicin
    • MNPR-101 RIT & MNPR-101-Zr
    • MNPR-101
    • MNPR-202
    • Collaborations
    • Intellectual Property
    • Publications
    • Investors
    • Overview
    • Annual Meeting
    • News / Events
    • Company Information
    • Stock Data
    • SEC Filings
    • Corporate Governance

    Terms and Conditions of Use

    © 2023 Monopar Therapeutics Inc. All Rights Reserved.